These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11518188)

  • 1. Role of sodium-hydrogen exchange in cardiac hypertrophy and heart failure: a novel and promising therapeutic target.
    Karmazyn M
    Basic Res Cardiol; 2001 Jul; 96(4):325-8. PubMed ID: 11518188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of Na-H exchange inhibitors for the treatment of heart failure.
    Karmazyn M
    Expert Opin Investig Drugs; 2001 May; 10(5):835-43. PubMed ID: 11322861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the myocardial sodium-hydrogen exchange for treatment of heart failure.
    Morris K
    Expert Opin Ther Targets; 2002 Jun; 6(3):291-8. PubMed ID: 12223070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myocardial Na+/H+ exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure.
    Karmazyn M; Sostaric JV; Gan XT
    Drugs; 2001; 61(3):375-89. PubMed ID: 11293648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition.
    Chen L; Chen CX; Gan XT; Beier N; Scholz W; Karmazyn M
    Am J Physiol Heart Circ Physiol; 2004 Jan; 286(1):H381-7. PubMed ID: 14684366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The myocardial sodium-hydrogen exchanger (NHE) and its role in mediating ischemic and reperfusion injury.
    Karmazyn M
    Keio J Med; 1998 Jun; 47(2):65-72. PubMed ID: 9659815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of NHE-1 in myocardial hypertrophy and remodelling.
    Karmazyn M; Kilić A; Javadov S
    J Mol Cell Cardiol; 2008 Apr; 44(4):647-53. PubMed ID: 18329039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes.
    Gan XT; Gong XQ; Xue J; Haist JV; Bai D; Karmazyn M
    Cardiovasc Res; 2010 Jan; 85(1):79-89. PubMed ID: 19687166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling.
    Baartscheer A; Hardziyenka M; Schumacher CA; Belterman CN; van Borren MM; Verkerk AO; Coronel R; Fiolet JW
    Br J Pharmacol; 2008 Jul; 154(6):1266-75. PubMed ID: 18493245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Na(+)/H(+) exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium.
    Yoshida H; Karmazyn M
    Am J Physiol Heart Circ Physiol; 2000 Jan; 278(1):H300-4. PubMed ID: 10644613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cardiac Na-H exchanger: a key downstream mediator for the cellular hypertrophic effects of paracrine, autocrine and hormonal factors.
    Fliegel L; Karmazyn M
    Biochem Cell Biol; 2004 Dec; 82(6):626-35. PubMed ID: 15674430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide.
    Karmazyn M
    Ann N Y Acad Sci; 1999 Jun; 874():326-34. PubMed ID: 10415544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury.
    Levitsky J; Gurell D; Frishman WH
    J Clin Pharmacol; 1998 Oct; 38(10):887-97. PubMed ID: 9807968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1).
    Tracey WR; Allen MC; Frazier DE; Fossa AA; Johnson CG; Marala RB; Knight DR; Guzman-Perez A
    Cardiovasc Drug Rev; 2003; 21(1):17-32. PubMed ID: 12595915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular sodium hydrogen exchange inhibition and clinical myocardial protection.
    Mentzer RM; Lasley RD; Jessel A; Karmazyn M
    Ann Thorac Surg; 2003 Feb; 75(2):S700-8. PubMed ID: 12607715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na(+)/H(+) exchanger.
    Camilión de Hurtado MC; Portiansky EL; Pérez NG; Rebolledo OR; Cingolani HE
    Cardiovasc Res; 2002 Mar; 53(4):862-8. PubMed ID: 11922896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Na(+)/H(+) exchanger: a target for cardiac therapeutic intervention.
    Karmazyn M; Sawyer M; Fliegel L
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):323-35. PubMed ID: 16101565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?
    Avkiran M; Cook AR; Cuello F
    Curr Opin Pharmacol; 2008 Apr; 8(2):133-40. PubMed ID: 18222727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NHE-1: still a viable therapeutic target.
    Karmazyn M
    J Mol Cell Cardiol; 2013 Aug; 61():77-82. PubMed ID: 23429008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation.
    Kilić A; Huang CX; Rajapurohitam V; Madwed JB; Karmazyn M
    J Pharmacol Exp Ther; 2014 Dec; 351(3):492-9. PubMed ID: 25216745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.